(AVNS) Avanos Medical - Ratings and Ratios

Avanos Medical, Inc. is a medical technology company that offers a diverse range of medical device solutions across various regions, including North America, Europe, and the Asia Pacific. The companys product portfolio includes digestive health solutions, such as enteral feeding tubes and patient feeding systems, as well as non-opioid pain management products, including surgical pain pumps and cold compression therapy systems. Additionally, Avanos provides interventional pain solutions, featuring minimally invasive pain-relieving therapies for chronic pain conditions.

The companys products are marketed directly to healthcare providers, hospitals, and facilities, as well as through third-party distributors. With a history dating back to 2014, Avanos Medical was formerly known as Halyard Health, Inc. before rebranding in June 2018. Headquartered in Alpharetta, Georgia, the company has established itself as a player in the healthcare supplies industry.

From a technical analysis perspective, AVNS stock is currently trading near its 52-week low, with a last price of $12.17. The stock is below its 20-day and 50-day simple moving averages (SMA20 and SMA50), indicating a short-term downtrend. However, the Average True Range (ATR) of 0.37, or 3.07%, suggests relatively low volatility. Considering the significant gap between the current price and the 52-week high of $24.69, there is potential for a rebound.

Fundamentally, Avanos Medical has a market capitalization of $572.04 million. Although the company has a negative Return on Equity (RoE) of -37.34, indicating significant losses, the absence of a P/E ratio may suggest that the company is not currently profitable or has highly variable earnings. To forecast the stocks performance, we can consider the technical and fundamental data. If the company can address its profitability issues, a potential rebound in the stock price could be driven by a return to profitability and improved investor sentiment. Based on the current SMA20 and SMA50, a potential short-term target could be around $12.50-$12.60, while a more significant recovery would require a break above the SMA200 at $16.71.

Forecasting the stocks performance, we can anticipate a potential short-term trading opportunity between $12.00 and $12.50, driven by the low volatility and oversold conditions. However, a more substantial recovery would require significant improvements in the companys fundamental performance, including a return to profitability and a reduction in losses. If Avanos Medical can address these challenges, a potential long-term target could be around $18.00-$20.00, representing a 30-50% increase from current levels.